Spot on against autoimmune diseases and chronic inflammations

September 25, 2014, Technical University Munich
Based on structural data of the immunoproteasome researchers at Technische Universität München found an inhibitor, which selectively inactivates the immunoproteasome without influencing the constitutive proteasome. Credit: Prof. Michael Groll / TUM

Multiple sclerosis, type 1 diabetes and lupus are autoimmune diseases in which the immune cells can no longer differentiate between friend and foe and thus attack the body's own tissue. Here, the immunoproteasome, which supplies the immune system with information on processes within the cell, plays a central role. Chemists at Technische Universität München have now discovered a way to inhibit its functionality, thereby laying the foundation for possible optimizations of existing medications.

The functions as the body's police force, protecting it from intruders like bacteria and viruses. However, in order to ascertain what is happening in the cell it requires information on the foreign invaders. This task is assumed by so-called immunoproteasomes. These are cylindrical protein complexes that break down the protein structures of the intruders into fragments that can be used by the defense system.

"In like rheumatism, or as well as severe inflammations a significantly increased immunoproteasome concentration can be measured in the cells," explains Prof. Michael Groll at the TUM Chair of Biochemistry. "The deactivation of this degradation machinery suppresses the regeneration of immune signaling molecules, which, in turn, prevents an excessive immune reaction."

Subtle but significant differences

For some time now, scientists have been on the lookout for new active substances that block immunoproteasomes in a targeted manner without inhibiting the so-called constitutive proteasomes also present in cells. They break down defective or no longer required proteins and are thus responsible for cellular recycling. Notably cell death occurs, when both the constitutive proteasomes and the immunoproteasomes are inactivated.

In early 2012 the research team led by Groll fulfilled a prerequisite for designing specific active substances: They solved the crystal structure of the immunoproteasome, allowing them to spot the subtle but significant differences between the otherwise nearly identical structures.

Special mode of action

The potential drug that the researchers developed is based on the epoxyketon ONX 0914, an immunoproteasome inhibitor that is already used in clinical trials. The scientists replaced the epoxyketon with a sulfonylflouride group and modified its positioning on the inhibitor. The result was a new compound that selectively inhibits the immunoproteasome without influencing the constitutive proteasome.

First author Christian Dubiella explains what makes the discovered mechanism so special: "Normally inhibitors clog up the active center of the enzyme and thereby disable its functionality. The substance synthesized by us, however, attaches to its target, causing the active center to destroy itself, and then gets detached after successful inactivation." Especially the insights into the atomic mechanisms that were uncovered using X-ray structure analysis open the door to the custom-tailored development of immunoproteasome inhibitors. This may pave the road for a future generation of medications.

Explore further: Immunoproteasome crystal structure determined

More information: Selective Inhibition of the Immunoproteasome by Ligand-Induced Crosslinking of the Active Site, Christian Dubiella, Haissi Cui, Malte Gersch, Arwin J. Brouwer, Stephan A. Sieber, Achim Krüger, Rob M. J. Liskamp, Michael Groll, Angewandte Chemie, Early view, September 22, 2014 – DOI: 10.1002/anie.201406964

Related Stories

Immunoproteasome crystal structure determined

February 16, 2012
Like a shredder, the immunoproteasome cuts down proteins into peptides that are subsequently presented on the cellular surface. The immune system can distinguish between self and nonself peptides and selectively kills cells ...

Modified immune cells seek and destroy melanoma

June 24, 2013
In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of ...

Protein identified as important trigger of antiviral response

May 7, 2014
Cells have to protect themselves: against damage in their genetic material for one thing, but also against attack from the outside, by viruses for example. They do this by using different mechanisms: special proteins search ...

Genetic signal prevents immune cells from turning against the body

August 14, 2014
When faced with pathogens, the immune system summons a swarm of cells made up of soldiers and peacekeepers. The peacekeeping cells tell the soldier cells to halt fighting when invaders are cleared. Without this cease-fire ...

Discovery paves the way for a new generation of chemotherapies

September 9, 2014
A new mechanism to inhibit proteasomes, protein complexes that are a target for cancer therapy, is the topic of an article published in the journal Chemistry & Biology. The first author of the study is Daniela Trivella, researcher ...

Recommended for you

A Trojan Horse delivery for treating a rare, potentially deadly, blood-clotting disorder

September 21, 2018
In proof-of-concept experiments, University of Alabama at Birmingham researchers have highlighted a potential therapy for a rare but potentially deadly blood-clotting disorder, TTP. The researchers deliver this therapeutic ...

Study shows surprise low-level ozone impact on asthma patients

September 21, 2018
A new study led by UNC School of Medicine researchers indicates that ozone has a greater impact on asthma patients than previously thought. The study, published in the Journal of Allergy and Clinical Immunology, recruited ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

Gut fungus exacerbates asthma in antibiotic-treated mice

September 20, 2018
A non-pathogenic fungus can expand in the intestines of antibiotic-treated mice and enhance the severity of allergic airways disease, according to a study published September 20 in the open-access journal PLOS Pathogens by ...

Paracetamol use in infancy is linked to increased risk of asthma in some teenagers

September 17, 2018
Children who take paracetamol during their first two years of life may be at a higher risk of developing asthma by the age of 18, especially if they have a particular genetic makeup, according to new research presented at ...

Cord blood clue to respiratory diseases

September 15, 2018
New research has found children born in the last three months of the year in Melbourne may have a greater risk of developing respiratory diseases such as asthma.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.